February 19th 2024
Amid shifting healthcare cost strategies, how manufacturers can apply past lessons to best support patients and help boost drug adherence.
February 7th 2024
As the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.
February 5th 2024
Higher prices of insulin attributed to significant annual increases, outpacing general inflation.
February 1st 2024
A look at how legislation—and the wider quest for more transparency on drug costs and reimbursement—may impact manufacturer product launch and pricing strategies in the years ahead.
November 14th 2023
Proposed legislation aims to address pharmacy benefit manager tactics to reduce prescription drug prices.
Novo Nordisk to Discontinue Levemir for Diabetes Mellitus
Novo Nordisk said it will continue providing Levemir vials and the Levemir FlexPen for diabetes control while supplies last, until the full product discontinuation at the end of 2024.
Optum Rx Moves Eight Preferred Insulin Products to Lowest Cost Tier
Eight rapid-, short-, and long-acting insulin products will move to tier one preferred status, which limits out-of-pocket spending to $35 or less for patients with diabetes.
The Value of Care: Q&A With Peter Rubin, Executive Director at No Patient Left Behind
Rubin speaks about how drugs aren’t being properly valued.
Driving Patient-First Affordability in Seconds, Not Days: Accelerating Time to Therapy
Webinar Date/Time: Thu, Oct 12, 2023 2:00 PM EDT
Strategies for Success in an Evolving Commercialization Landscape
A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.
Current Drug Affordability Challenges
In this exclusive Q&A, Vishali Amin, chief of staff to the office of the president and senior director of customer success for Kalderos, discusses the biggest hurdles to drug affordability, how patients can become aware of drug discounts, how drugs are selected for regulatory discount programs, and drug pricing strategies.
What’s Next for Biopharma Under the Inflation Reduction Act
As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.
What Can Pharma Do for Patients Post IRA?
Kevin Hagan, president and CEO of the PAN Foundation, discusses how pharma can help Medicare patients post-IRA reform.
Pharma USA 2023: IRA Impact on Patients
Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients.
Confronting a Challenging Macroeconomic Environment with Innovation
Webinar Date/Time: Thu, Mar 16, 2023 11:00 AM EDT
The Price of Innovation: ‘Paying for a Cure’ Remains Costly Proposition
Curative-type therapies offer great hope in further transforming treatments for cancer and other diseases, but addressing the economics of these products—and ultimately the cost-benefit equation—is daunting. What is being done to smooth the path for pricing and reimbursement?
Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a Catch
Value-based price for access (VBPA) may increase access of specialty drugs for patients.
Q&A With Paul Ford, co-founder and president, DS9 Capital
Ford discusses how rising drug costs in impact patients, and how they can either avoid them or find less-expensive options.
Real-World Evidence Is Becoming a Pivotal Component in Chinese Healthcare
Its use enables key processes such as early access, regulatory approval, and reimbursement listing.
Aligning Contracting to Solve for Payer Risks Is a Win for Biopharma, Payers, and Patients
Upcoming regulatory changes to create new opportunity for specialized offerings.
A Complex Patent & Pricing Picture: Regulating Psychedelics More of a Journey Than a Trip
Pharma and legal experts weigh in on the rush to secure intellectual property around psychedelic medicines, the value imperative that should govern pricing strategies, and the likely long-haul battle for more widespread decriminalization of these drugs.
Drug Costs Central Issue in Budget Battles
As Congress struggles to reach agreement on funding for leading social and spending initiatives and to avoid default on government borrowing, the White House is emphasizing that reduced spending on prescription drugs can help offset some of the steep costs.
Generics Makers Also Fight Price Controls
The Democratic proposal to authorize price negotiations on costly medicines covered by Medicare and to penalize firms that raise prices faster than inflation has drawn opposition pharma and biotech companies. More surprisingly, generic companies also are objecting to the changes on the table.
China 2021 National Reimbursement Drug List Outlook
The 2021 National Reimbursement Drug List (NRDL) process has been unfolding in China since June this year, with several key themes emerging. Building on Simon-Kucher’s experience with the NRDL, the authors make three recommendations on negotiation strategies going into the process.
Will Pharma Accept the Democrats’ Drug Pricing Deal – Or Continue to Fight Reform?
Democratic leaders in the House and Senate appear to have reached a compromise on a relatively modest plan for controlling prices on certain prescription drugs.
Improving Readiness for Volume-Based Procurement in China
Volume-based procurement (VoBP) has been gathering momentum in China, both at national and regional levels. Major pharmaceutical players stand to see large impacts on their branded generics portfolio, and need to move fast to improve organizational and system readiness.
Pharma Blocks Democrats’ Drug Pricing Plan
Democrats failed to gain sufficient support this week to advance long-debated legislation to permit Medicare drug price negotiations.
Will Price Controls Limit Drug Development? The Debate Heats Up
Legislative proposals for curbing outlays on prescription drugs have moved to center stage, as Congress looks hard for ways to pay for costly initiatives to repair the nation’s infrastructure, offset global warming and expand health care programs.
Biden Highlights Drug Pricing Reforms to Advance Legislative Agenda
The White House is looking to pay for some of its prime social and health initiatives by reducing outlays for prescription drugs, according to an announcement by President Biden.
Drug Prices Targeted in Biden Competition Initiative
A broad White House proposal to advance competition in major U.S. industries features several measures intended to make medicines more affordable for patients.
How a “Push and Pull” Approach Can Maximize Innovation Value through HTAs
How can companies adapt their single evidence package at launch into multiple, tailored versions for HTAs that vary across different countries and regions?
Evolving a Market Access Strategy to Improve Patient Access
David Bower and Agata Wiśniowska discuss how addressing payer needs in the product development process can help companies increase patient access to their novel treatments.
SPBMs: Impact on Accessibility & Affordability of Gene Therapies for Rare and Orphan Diseases
The introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.
Drug Pricing Moves to Top of Legislative Agenda
With Sen. Bernie Sanders leading the charge on Capitol Hill, the campaign to limit U.S. outlays for prescription drugs has accelerated.
Minimizing the Risk of Mistakes in HTA
We all make mistakes — and that includes those involved in Health Technology Assessment (HTA). Following an error made by ICER this year, Leela Barham looks at similar mistakes made in the past and what can be done about them.
2 Commerce Drive Cranbury, NJ 08512